Prodromal Alzheimer's disease

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
5 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Monoclonal antibody (neural) 1 substance
Phase III: 1 Phase II: 3 Phase I (Other): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial

Phase II

3 trials
  • F. Hoffmann-La Roche AG Commercial
    RO7269162
    2023-506183-13-00 6 countries 2024 n=202
    Ended
  • Barcelonabeta Brain Research Center Academic
    [18F]DED
    2025-523284-37-00 1 country n=300
    Pending
  • Region Skane Academic
    2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
    2024-511842-38-00 1 country 2017 n=2,450
    Recruiting

Phase I (Other)

1 trial
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-514634-20-00 3 countries 2025 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 1 Phase I (Other) 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Eisai Limited Commercial 1 Phase III 0
Barcelonabeta Brain Research Center Academic 1 Phase II 0
Region Skane Academic 1 Phase II 1
New trials by year
2019
1
2024
1
2025
1
← All indication landscapes